PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9534726

Radionuclide developments.

C M Medley·G C Vivian
View original source ↗Export metadata ↓

Abstract

This review considers a number of recent important developments in nuclear medicine, and possible future introductions, priority being given to those products which are most likely to find a place in clinical practice. This includes both novel radiopharmaceuticals and progress with new types of imaging equipment. Three areas are chosen as being of particular importance: brain imaging, heart imaging, and diagnosis and therapy of cancer. In the brain, the clinical value of imaging regional cerebral blood flow and certain aspects of the neuroreceptor/neurotransmitter system are discussed. Cardiac imaging is considered in the light of recent work on diagnosis and risk assessment, investigating the hibernating myocardium, and the possible place of fatty acid imaging. Both diagnosis and therapy of cancer are increasingly important, and the use of radionuclides in these areas in considered.

Explore related subjects

Bone NeoplasmsBrainCerebrovascular DisordersHeartHumansRadioimmunotherapyRadionuclide ImagingRadiotherapyThrombosisJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C M Medley, G C Vivian. 1997. Radionuclide developments.. https://doi.org/10.1259/bjr.1997.0016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

Most patients with multiple myeloma (MM) present with symptoms, have evidence of generalized disease, and require chemotherapy promptly to reduce the malignant clone. Some patients present with a local symptom from a single plasmacytoma but no myeloma elsewhere. Such patients usually become free of symptoms after local radiotherapy. In patients with MM without symptoms, the diagnosis is made on the basis of screening laboratory tests. In patients with either solitary plasmacytoma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression.

Bone Neoplasms↗
PubMed2000

pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels.

A key difference among the three structurally similar pRB family members is that only pRB is a tumor suppressor. Identification of distinctive functional differences between pRB and p107/p130 therefore holds promise for a better understanding of the tumor suppression mechanisms of pRB. Enigmatically, pRB and p107 have been shown to have indistinguishable growth suppression activities when studied in the pRB-deficient Saos-2 cell system. In this study, we discovered that, when expressed at physiologically relevant levels, pRB and p107 had distinctive effects in causing growth suppression. pRB induced cellular p130 levels while p107 repressed them. p107, but not pRB, blocked cells inside S phase in addition to G1 arrest. In contrast, no qualitative differences were identified in their abilities to repress the expression of a set of suspected pRB/E2F repression target genes. These results indicate that pRB and p107 possess different growth suppression effects, despite the fact that they have similar E2F repression effects.

Bone Neoplasms↗